(Posted: 3/12/97)
Note: The following summaries include only those safety-related sections that have been modified, and therefore do not contain all the information needed for safe and effective prescribing. Contact the manufacturer for the complete labeling/package insert.
NB: Comparison made to 1997 Physicians' Desk Reference (PDR), if drug's labeling included in the PDR.
ACEON
[January 8, 1997: Rhone-Poulenc Rorer]
DEPO-PROVERA
(medroxyprogesterone acetate suspension)
[January 31, 1997: Pharmacia & Upjohn]
FAMVIR
[January 13, 1997: SmithKline Beecham]
LOVENOX
[January 27, 1997: Rhone-Poulenc Rorer]
LUPRON DEPOT-PED
[January 10, 1997: TAP]
(NB: Changes appear in 1997 PDR)
Return to Quick Reference
MAXZIDE
[January 10, 1997: Mylan]
Carcinogenesis: A specific statement that long-term studies with Maxzide (triamterene/hydrochlorothiazide combination) have not been conducted replaces prior statement regarding evaluation of mutagenic or carcinogenic potential.
Triamterene: Prior statements that studies have not been performed to determine triamterene's carcinogenic or mutagenic potential, and that reproductive studies in rats at doses up to 30 times the human dose revealed no evidence of impaired fertility, have been replaced by a revised new sub-subsection that delineates the results of studies conducted under the auspices of the National Toxicology Program [see sub-subsection in package insert].
Hydrochlorothiazide: Revised to present data from rodent (mice and rats) studies in terms of Maximum Recommended Human Dose (MRHD) on a body-surface area basis, in addition to classifying the previously included mg/kg/day data in terms of MHRD on a body-weight basis [see sub-subsection in package insert].
Mutagenesis: A specific statement reiterates previous notation that studies of Maxzide (triamterene/hydrochlorothiazide combination) mutagenic potential have not been performed.
Triamterene (new sub-subsection): Results of mutagenesis studies that have been conducted are delineated [see sub-subsection in package insert].
Hydrochlorothiazide: Previously included information regarding mutagenesis studies now placed in this specific sub-subsection.
Impairment of Fertility: New statement: "Studies of the effects of Maxzide, the triamterene/ hydrochlorothiazide combination, or of triamterene alone on animal reproductive function have not been conducted."
Hydrochlorothiazide: Revised to present data from rodent (mice and rats) studies in terms of MRHD on a body-surface area basis, in addition to mg/kg/day MRHD data [see sub-subsection in package insert].
Pregnancy Category C: Pregnancy Category remains C.
Teratogenic Effects, Maxzide (new sub-subsection replacing Teratogenic Effects): While noting as before that animal reproductive studies with Maxzide have not been conducted, results of a One Generation Study in the rat using an approximated Maxzide composition have been added [see sub-subsection in package insert].
In addition, the following paragraph has been added: "The safe use of Maxzide in pregnancy has not been established since there are no adequate and well-controlled studies with Maxzide in pregnant women. Maxzide should be used during pregnancy only if the potential benefit justifies the risk to the fetus."
Triamterene: Revised to present data from rats studies in terms of MRHD on a body-surface area basis, and in specifically noting MRHD on a body-weight basis, revised previously included human dose data [see sub-subsection in package insert].
Hydrochlorothiazide: Revised to present data from rodent (mice and rats) studies in terms of MRHD on body-weight and body-surface area bases [see sub-subsection in package insert].
NB: Both Teratogenic Effects, Triamterene and Teratogenic Effects, Hydrochlorothiazide include previous notation that since animal reproductive studies are not always predictive of human response, Maxzide should be used during pregnancy only if clearly needed.
Nonteratogenic Effects: In statement that thiazides and triamterene cross the placental barrier and appear in cord blood, "of animals" removed. Pancreatitis added to delineated adverse reactions that have occurred in the adult (replacing "adults") that are possible hazards to the fetus if thiazides and triamterene (replacing "Maxzide") are used in pregnant women.
Nursing Mothers: Previous notation replaced by: "Thiazides and triamterene in combination have not been studied in nursing mothers. Triamterene appears in animal milk and this may occur in humans. Thiazides are excreted in human breast milk. If use of the combination drug product is deemed essential, the patient should stop nursing."
NOROXIN
[January 15, 1997: Merck]
NORVASC
[January 8, 1997: Pfizer]
NORVIR
[January 8, 1997: Abbott]
"Hepatic transaminase elevations exceeding 5 times the upper limit of normal, clinical hepatitis, and jaundice have occurred in patients receiving Norvir alone or in combination with other antiretroviral drugs (see Table 5). There may be an increased risk for transaminase elevations in patients with underlying hepatitis B or C. Therefore, caution should be exercised when administering Norvir to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis.
"There have been postmarketing reports of hepatic dysfunction, including some fatalities. These have generally occurred in patients taking multiple concomitant medications and/or with advanced AIDS. A definitive causal relationship has not been established."
OXYCONTIN
[January 6, 1997: Purdue Pharma L.P.]
PERIDEX
[January 8, 1997: Procter and Gamble]
Statement "No instances of permanent taste alteration due to Peridex have been reported." has been revised to read: "Rare instances of permanent taste alteration following Peridex use have been reported via postmarketing product surveillance."
Usage in Pregnancy: Entire subsection deleted and replaced with "Pregnancy: Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at chlorhexidine gluconate doses up to 300md/kg/day and 40 mg/kg/day, respectvely, and have not revealed evidence of harm to the fetus. However, adequate and well-controlled studies in pregnant women have not been done. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."
Carcinogenesis, Mutagenesis, and Impairment of Fertility (replaces prior Carcinogenesis, Mutagenesis subsection): Revised with a more accurate statement reflecting the actual results of the rat study and addition of information regarding impaired fertility. (See complete subsection in package insert.)
"Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with use of chlorhexidine gluconate rinse. The following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1.0%.
"Among postmarketing reports, the most frequently reported oral mucosal symptoms associated with peridex are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia.
"Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using Peridex.
There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using Peridex."
PROCARDIA XL
[January 8, 1997: Pfizer]
ZOVIRAX
[January 8, 1997: Glaxo Wellcome]